Bendamustine

Medicare

Part B (clinician-administered)

Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Bendeka and Belrapzo are branded; generic bendamustine is available.

Commercial insurance

covered on label

Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens. Plans may prefer a specific bendamustine product.

Assistance programmes

• PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
• HealthWell Foundation
• CancerCare Co-Payment Assistance Foundation
• Patient Advocate Foundation Co-Pay Relief

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.

Appraised for

First-line CLL (Binet B/C) when fludarabine combination is not appropriate

Notes

Generic; also used in lymphoma regimens (BR) and as the partner in TA472 and TA649.

NHS England

Routinely funded for the appraised indication (or via managed access)

Sources: NICE TA216 · SMC advice: bendamustine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.